Association of BTG2, CYR61, ZFP36, and SCD gene polymorphisms with graves' disease and ophthalmopathy

Thyroid

Volumn 24, Issue 7, 2014, Pages 1156-1161

  Planck, Tereza ^a,b   Shahida, Bushra ^b   Sjögren, Marketa ^b   Groop, Leif ^a,b   Hallengren, Bengt ^a,b   Lantz, Mikael ^a,b  

^a LUND UNIVERSITY HOSPITAL   (Sweden)

^b LUND UNIVERSITY   (Sweden)

Author keywords

[No Author keywords available]

Indexed keywords

ACYL COENZYME A DESATURASE; BTG FAMILY MEMBER 2 PROTEIN; CYSTEINE RICH PROTEIN 61; PROTEIN; TRISTETRAPROLIN; UNCLASSIFIED DRUG; BTG2 PROTEIN, HUMAN; IMMEDIATE EARLY PROTEIN; SCD1 PROTEIN, HUMAN; TUMOR SUPPRESSOR PROTEIN; ZFP36 PROTEIN, HUMAN;

ADULT; ARTICLE; CONTROLLED STUDY; ETHNICITY; EYE DISEASE; FEMALE; GENE FREQUENCY; GENE LINKAGE DISEQUILIBRIUM; GENE OVEREXPRESSION; GENETIC ASSOCIATION; GENETIC VARIABILITY; GENOTYPE; GRAVES DISEASE; HUMAN; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; SINGLE NUCLEOTIDE POLYMORPHISM; SMOKING; SWEDEN; ENDOCRINE OPHTHALMOPATHY; GENETIC PREDISPOSITION; GENETICS; GENOTYPE ENVIRONMENT INTERACTION; MIDDLE AGED;

ADULT; CYSTEINE-RICH PROTEIN 61; FEMALE; GENE FREQUENCY; GENE-ENVIRONMENT INTERACTION; GENETIC ASSOCIATION STUDIES; GENETIC PREDISPOSITION TO DISEASE; GENOTYPE; GRAVES DISEASE; GRAVES OPHTHALMOPATHY; HUMANS; IMMEDIATE-EARLY PROTEINS; MALE; MIDDLE AGED; POLYMORPHISM, SINGLE NUCLEOTIDE; STEAROYL-COA DESATURASE; SWEDEN; TRISTETRAPROLIN; TUMOR SUPPRESSOR PROTEINS;

EID: 84903978111     PISSN: 10507256     EISSN: 15579077     Source Type: Journal    
DOI: 10.1089/thy.2013.0654     Document Type: Article

References (39)

1. Tomer Y 2010 Genetic susceptibility to autoimmune thyroid disease: Past, present, and future. Thyroid 20:715-725
2. Bahn RS 2010 Graves' ophthalmopathy. New Engl J Med 362:726-738
3. Vaidya B, Imrie H, Perros P, Dickinson J, McCarthy MI, Kendall-Taylor P, Pearce SH 1999 Cytotoxic T lymphocyte antigen-4 (CTLA-4) gene polymorphism confers susceptibility to thyroid associated orbitopathy. Lancet 354: 743-744
4. Park YJ, Chung HK, Park DJ, Kim WB, Kim SW, Koh JJ, Cho BY 2000 Polymorphism in the promoter and exon 1 of the cytotoxic T lymphocyte antigen-4 gene associated with autoimmune thyroid disease in Koreans. Thyroid 10: 453-459
5. Villanueva R, Inzerillo AM, Tomer Y, Barbesino G, Meltzer M, Concepcion ES, Greenberg DA, MacLaren N, Sun ZS, Zhang DM, Tucci S, Davies TF 2000 Limited genetic susceptibility to severe Graves' ophthalmopathy: No role for CTLA-4 but evidence for an environmental etiology. Thyroid 10:791-798
6. Allahabadia A, Heward JM, Nithiyananthan R, Gibson SM, Reuser TT, Dodson PM, Franklyn JA, Gough SC 2001 MHC class II region, CTLA4 gene, and ophthalmopathy in patients with Graves' disease. Lancet 358:984-985
7. Zaletel K, Krhin B, Gaberscek S, Pirnat E, Hojker S 2002 The influence of the exon 1 polymorphism of the cytotoxic T lymphocyte antigen 4 gene on thyroid antibody production in patients with newly diagnosed Graves' disease. Thyroid 12:373-376
8. Yin X, Latif R, Bahn R, Davies TF 2012 Genetic profiling in Graves' disease: Further evidence for lack of a distinct genetic contribution to Graves' ophthalmopathy. Thyroid 22:730-736
9. Hagg E, Asplund K 1987 Is endocrine ophthalmopathy related to smoking?. Br Med J (Clin Res Ed) 295:634-635
10. Thornton J, Kelly SP, Harrison RA, Edwards R 2007 Cigarette smoking and thyroid eye disease: A systematic review. Eye (Lond) 21:1135-1145
11. Wiersinga WM, Bartalena L 2002 Epidemiology and prevention of Graves' ophthalmopathy. Thyroid 12:855-860
12. Bartalena L, Marcocci C, Bogazzi F, Manetti L, Tanda ML, Dell'Unto E, Bruno-Bossio G, Nardi M, Bartolomei MP, Lepri A, Rossi G, Martino E, Pinchera A 1998 Relation between therapy for hyperthyroidism and the course of Graves' ophthalmopathy. New Engl J Med 338:73-78
13. Tallstedt L, Lundell G, Torring O, Wallin G, Ljunggren JG, Blomgren H, Taube A 1992 Occurrence of ophthalmopathy after treatment for Graves' hyperthyroidism. The Thyroid Study Group. New Engl J Med 326:1733-1738
14. Traisk F, Tallstedt L, Abraham-Nordling M, Andersson T, Berg G, Calissendorff J, Hallengren B, Hedner P, Lantz M, Nystrom E, Ponjavic V, Taube A, Torring O, Wallin G, Asman P, Lundell G 2009 Thyroid-Associated ophthalmopathy after treatment for Graves' hyperthyroidism with antithyroid drugs or iodine-131. J Clin Endocrinol Metab 94:3700-3707
15. Lantz M, Vondrichova T, Parikh H, Frenander C, Ridderstrale M, Asman P, Aberg M, Groop L, Hallengren B 2005 Overexpression of immediate early genes in active Graves' ophthalmopathy. J Clin Endocrinol Metab 90:4784-4791
16. Planck T, Parikh H, Brorson H, Martensson T, Asman P, Groop L, Hallengren B, Lantz M Gene expression in Graves' ophthalmopathy and arm lymphedema: Similarities and differences. Thyroid 21:663-674
17. Canning MO, Ruwhof C, Drexhage HA 2003 Aberrancies in antigen-presenting cells and T cells in autoimmune thyroid disease. A role in faulty tolerance induction. Autoimmunity 36:429-442
18. Nilsson PM, Nilsson JA, Berglund G 2006 Populationattributable risk of coronary heart disease risk factors during long-Term follow-up: The Malmo Preventive Project. J Intern Med 260:134-141
19. Manjer J, Carlsson S, Elmstahl S, Gullberg B, Janzon L, Lindstrom M, Mattisson I, Berglund G 2001 The Malmo Diet and Cancer Study: Representativity, cancer incidence and mortality in participants and non-participants. Eur J Cancer Prev 10:489-499
20. International HapMap Consortium 2003 The International HapMap Project. Nature 426:789-796
21. Barrett JC, Fry B, Maller J, Daly MJ 2005 Haploview: Analysis and visualization of LD and haplotype maps. Bioinformatics 21:263-265
22. Hemminger BM, Saelim B, Sullivan PF 2006 TAMAL: An integrated approach to choosing SNPs for genetic studies of human complex traits. Bioinformatics 22:626-627
23. Purcell S, Cherny SS, Sham PC 2003 Genetic Power Calculator: Design of linkage and association genetic mapping studies of complex traits. Bioinformatics 19:149-150
24. Wellcome Trust Case Control Consortium, Maller JB, McVean G, Byrnes J, Vukcevic D, Palin K, Su Z, Howson JM et al 2012 Bayesian refinement of association signals for 14 loci in 3 common Diseases. Nat Genet 44:1294-1301
25. Purcell S, Neale B, Todd-Brown K, Thomas L, Ferreira MA, Bender D, Maller J, Sklar P, de Bakker PI, Daly MJ, Sham PC 2007 PLINK: A tool set for whole-genome association and population-based linkage analyses. Am J Hum Genet 81:559-575
26. Terra R, Luo H, Qiao X, Wu J 2008 Tissue-specific expression of B-cell translocation gene 2 (BTG2) and its function in T-cell immune responses in a transgenic mouse model. Int Immunol 20:317-326
27. Kireeva ML, Mo FE, Yang GP, Lau LF 1996 Cyr61, a product of a growth factor-inducible immediate-early gene, promotes cell proliferation, migration, and adhesion. Mol Cell Biol 16:1326-1334
28. Yeger H, Perbal B 2007 The CCN family of genes: A perspective on CCN biology and therapeutic potential. J Cell Commun Signal 1:159-164
29. Haas CS, Creighton CJ, Pi X, Maine I, Koch AE, Haines GK, Ling S, Chinnaiyan AM, Holoshitz J 2006 Identification of genes modulated in rheumatoid arthritis using complementary DNA microarray analysis of lymphoblastoid B cell lines from disease-discordant monozygotic twins. Arthritis Rheum 54:2047-2060
30. Zhang Q, Wu J, Cao Q, Xiao L, Wang L, He D, Ouyang G, Lin J, Shen B, Shi Y, Zhang Y, Li D, Li N 2009 A critical role of Cyr61 in interleukin-17-dependent proliferation of fibroblast-like synoviocytes in rheumatoid arthritis. Arthritis Rheum 60:3602-3612
31. Kim JN, Kim HJ, Jeong SH, Kye YC, Son SW 2011 Cigarette smoke-induced early growth response-1 regulates the expression of the cysteine-rich 61 in human skin Dermal fibroblasts. Exp Dermatol 20:992-997
32. Lai WS, Carballo E, Strum JR, Kennington EA, Phillips RS, Blackshear PJ 1999 Evidence that tristetraprolin binds to AU-rich elements and promotes the deadenylation and destabilization of tumor necrosis factor alpha mRNA. Mol Cell Biol 19:4311-4323
33. Taylor GA, Carballo E, Lee DM, Lai WS, Thompson MJ, Patel DD, Schenkman DI, Gilkeson GS, Broxmeyer HE, Haynes BF, Blackshear PJ 1996 A pathogenetic role for TNF alpha in the syndrome of cachexia, arthritis, and autoimmunity resulting from tristetraprolin (TTP) deficiency. Immunity 4:445-454
34. Carrick DM, Chulada P, Donn R, Fabris M, McNicholl J, Whitworth W, Blackshear PJ 2006 Genetic variations in ZFP36 and their possible relationship to autoimmune diseases. J Autoimmun 26:182-196
35. Almendral JM, Sommer D, Macdonald-Bravo H, Burckhardt J, Perera J, Bravo R 1988 Complexity of the early genetic response to growth factors in mouse fibroblasts. Mol Cell Biol 8:2140-2148
36. Inuzuka H, Nanbu-Wakao R, Masuho Y, Muramatsu M, Tojo H, Wakao H 1999 Differential regulation of immediate early gene expression in preadipocyte cells through multiple signaling pathways. Biochem Biophys Res Commun 265:664-668
37. Rosen ED 2002 The molecular control of adipogenesis, with special reference to lymphatic pathology. Ann NY Acad Sci 979:143-158; discussion 188-196
38. Warensjo E, Ingelsson E, Lundmark P, Lannfelt L, Syvanen AC, Vessby B, Riserus U 2007 Polymorphisms in the SCD1 gene: Associations with body fat distribution and insulin sensitivity. Obesity (Silver Spring) 15:1732-1740
39. Wellcome Trust Case Control Consortium, Australo-Anglo-American Spondylitis Consortium, Burton PR, Clayton DG, Cardon LR, Craddock N, Deloukas P, Duncanson A, Kwiatkowski DP et al. 2007 Association scan of 14,500 nonsynonymous SNPs in four diseases identifies autoimmunity variants. Nat Genet 39:1329-1337